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Session: 242. Antifungals
Saturday, October 5, 2019: 12:15 PM
Background. Mold-active antifungal prophylaxis (ppx) is recommended in neutropenic patients with newly diagnosed AML or MDS. ISAV is an extended spectrum
triazole with superior tolerability, reliability of absorption, fewer drug–drug interactions, lack of QTc prolongation or need for therapeutic drug monitoring, approved for
the treatment of invasive aspergillosis (IA) and mucormycosis. NCT03019939 is an
investigator-initiated, phase 2 trial of PAP with ISAV in patients with AML/MDS.
Methods. Treatment-naïve adult patients with AML or MDS initiating remission-induction chemotherapy (RIC) received ISAV per the dosing recommendations
in the United States label until recovery from neutropenia (neutrophils (ANC) ≥ 0.5 ×
109/L) and attainment of complete remission (CR), occurrence of proven or probable
invasive fungal infection (IFI, EORTC/MSG criteria), or for a maximum of 12 weeks.
The primary endpoint was incidence of proven/probable IFI during the study period
(up to 30 days from the last dose of ISAV).
Results. 67 patients were enrolled (April 28, 2017 to February 14, 2019) and 60
patients were eligible for assessment (median age 67 years, 57 patients with AML, median ANC on enrollment was 660). Reasons for study completion were achievement of
CR with ANC recovery (n = 35), completion of 12 weeks of PAP (n = 9), possible IFI (n
= 7), investigator decision (n = 3), death (n = 2, 1 disease progression, 1 cardiac arrest),
proven/probable IFI (n = 3), and mild transaminitis, possibly ISAV-related (n = 2). The
median durations of neutropenia and ISAV ppx were 33 (7–86) and 31 (7–86) days,
respectively. One microbiologically-proven (gluteal abscess due to Candida glabrata)
and 2 cases of probable breakthrough IFIs (probable IA with positive galactomannan)
occurred (IFI incidence 5%). ISAV trough serum concentrations were available in 31
patients on both day 8 (median 3.74 µg/mL, 2.03–7.65) and day 15 (median 4.10 µg/
mL, 2.17–9.25), and were not significantly different.
Conclusion. ISAV is a safe and effective alternative for PAP in patients with
newly diagnosed AML/MDS undergoing RIC, with a breakthrough (proven/probable)
IFI rate of 5%. ISAV serum levels were adequate in patients with AML/MDS undergoing RIC. Pharmacological features make ISAV attractive for PAP in the era of recently
approved or emerging small-molecule AML therapies.
Disclosures. All authors: No reported disclosures.
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Session: 242. Antifungals
Saturday, October 5, 2019: 12:15 PM
Background.
Isavuconazole (ISZ), dosed as the pre-drug isavuconazonium
(ISM), is active against a wide variety of clinically important fungal pathogens. ISM
is approved for the treatment of invasive aspergillosis and mucormycosis in adults
≥18 years of age. We present our experience with ISM to treat proven or to prevent
fungal infection in pediatric patients.
Methods. In a retrospective review of patients who received ISM at our institution between April 2016 and April 2019, we abstracted demographic information,
primary diagnosis, indication for ISM therapy, ISZ serum concentrations if available,
and outcomes.
Results. Of 16 patients who received ISM, 12 were < 18 years of age (range
6–17 years). Underlying conditions included leukemia (n = 8), lymphoma (n = 1),
post BMT (n = 1), diabetes (n = 1), and cardiac transplant (n = 1). Nine (75%) had
proven invasive fungal infection with aspergillosis (n = 2), zygomycosis (n = 3), mixed
aspergillosis and zygomycosis (n = 2), mixed Rhizopus and Scedosporium (n = 1),
and pathology only (n = 1). Five of these 9 patients received combination ISM and
liposomal amphotericin initially, followed by monotherapy with ISM in 4 patients after
a mean of 26 days (range 6–63), and continued dual therapy in the fifth. The other 4
received liposomal amphotericin with or without other azoles prior to changing to
ISM monotherapy. ISM dosing was 10 mg/kg q8h on days 1 and 2, followed by q24
thereafter, up to a maximum of 372 mg/dose. There were 19 measured ISZ serum concentrations obtained from 8 patients after >1 week of verified inpatient dosing, ranging
from 1.0 to 7.5 mg/L, above the MIC in all cases when known. Five (42%) patients
died of underlying non-mycological causes, 1 (8%) died of progressive scedosporiosis,
and 6 (50%) improved. The two patients receiving ISM prophylaxis did not suffer a
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breakthrough fungal infection. ISM was well tolerated with no dose-limiting, drug-related toxicities noted.
Conclusion. ISM is a well-tolerated therapeutic option in pediatric patients at
risk for or with invasive mycosis. Only 1 of our 12 patients died from progressive fungal
disease.
Disclosures. All authors: No reported disclosures.
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Background. Early and adequate antibiotic treatment are the cornerstones to
improve clinical outcomes in patients with Bloodstream infections (BSI). Delays
in appropriate antimicrobial therapy have catastrophic consequences for patients
with BSI. Microbiological characterization of multi-drug-resistant pathogens
(MDRP) allow clinicians to provide appropriate treatments. Current available
microbiologic techniques may take-up to 96 hours to identify causative pathogens
and its resistant patterns. Therefore, there is an important need to develop rapid
diagnostic strategies for MDRP. However, rapid detection techniques are costly
and are not widely available. We tested a modified protocol designed to detect
Gram-negative bacilli (GNB) resistant to oximinocephalosporins and carbapenems from positive blood cultures.
Methods. This is a prospective, cohort study of consecutive patients with bacteremia. We developed a modified protocol using HB&L® system to detect MDRP. We
then attempted to determine accuracy, concordance and reduction of identification
time of this novel method in a reference hospital. Descriptive statistics and logistical
regressions were used.
Results. Ninety-six patients with BSI were included in the study. A total of 161
positive blood cultures were analyzed. Escherichia coli (50%, 81/161) was the most
frequently identified pathogen followed by Klebsiella pneumoniae (15%, 24/161)
and Pseudomonas aeruginosa (8%, 13/161). 32% of isolations had usual resistance
patters. However, in 29/161 (18%) of identified pathogens were producer of carbapenemasases and 21/161 (13%) of extended-spectrum β-lactamases. Concordance
among our HB&L® modified protocol and traditional method was 99% (159/161).
Finally, identification times were significantly shorter using our HB&L® modified
protocol than traditional methods (Mean, hours [SD], 20.8 [6.22] vs. 62.8 [6.22],
P < 0.001).
Conclusion. Here we provided novel evidence that using our HB&L® modified
protocol is an effective strategy to reduce the time to MDRP detection/identification;
with a great concordance rate when compared with the gold standard. Further studies
are needed to confirm these findings and to determine whether this method may improve clinical outcomes.
Disclosures. All authors: No reported disclosures.
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Background. Of the >100,000 people in the United States infected yearly with
non-tuberculosis mycobacteria (NTM), Florida has the highest yearly incidence and
prevalence of NTM disease. However, little has been documented on the epidemiology
and distribution of NTM disease within Central Florida.
Methods. A retrospective case review study was conducted from January, 2011
to December, 2017 at a large tertiary acute care medical center in Tampa, Florida to
identify all NTM infection cases. Demographics (age, sex at birth, ethnicity), comorbidities, HIV testing status, residential zip code, NTM species, and specimen sources
were collected.
Results. Of the 507 isolates, Mycobacterium abscessus group was the most common (45.4%; n = 230), and contained M. abscessus spp. abscessus (34.5%; n = 175),
M. abscessus spp. massilense (8.7%; n = 44), and M. abscessus spp. bolletii (1.18%; n
= 6). Other rapid growers were M. fortuitum species (6.9%; n = 35) and M. chelonae
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(2.56%; n = 13). Of the slower growers, M. gordonae (19.9%; n = 101) and M. avium
complex (8.28%; n = 42) were the most common. Of the M. avium complex, M. chimera was most common (4.9%; n = 25). Samples were mostly isolated from sputum
(51.7%; n = 262), bronchial lavage (26%; n = 132), skin and soft tissue (11%; n = 58),
and blood (7.1%; n = 36). Of the 361 unique patients, average age was 59.2 years (12 to
95 years), with 47.6% (n = 172) greater than 65 years of age, and mostly male 57.9% (n
= 208). Caucasians represented 73.4% (n = 265) of our cohort, and African Americans
and Hispanics represented 16.3% (n = 59) and 6.8% (n = 24), respectively. Most cases
were in those residing outside the Tampa Bay metro area 81.2% (n = 293/361). Notable
comorbidities included COPD (n = 83), cystic fibrosis (n = 41), lung transplant (n =
40), heart transplant (n = 12), pulmonary fibrosis (n = 12), and renal transplant (n = 7).
A total of 145 individuals received HIV testing at the hospital facility, and of these 44
individuals were living with HIV.
Conclusion. This study identified a diversity of NTM species across a wide
geographical and demographic distribution in the endemic Central Florida region. M. abscessus group had the highest prevalence. This is valuable in understanding which populations are at risk for developing NTM infection in this area
of Florida.
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